Overview of treatment of hepatitis B: key approaches and clinical challenges.

The development of nucleoside analogues has been a major advance in the treatment of hepatitis B; however, prolonged monotherapy is associated with drug resistance. Currently, no data in humans indicate that a combination of nucleoside analogues leads to enhanced efficacy. New nucleoside analogues with greater inhibitory effects on hepatitis B virus (HBV) replication being developed could prove to be more effective or less likely to be associated with viral resistance. Interferon still has a role to play in the management of chronic HBV infection. Recent data indicate that the response to interferon may be determined in part by differences in genotype. From a theoretical perspective, a combination of pegylated interferon with one or more nucleosides could induce a higher rate of virological response. Additional studies are needed to further address these issues.

[1]  R. Carithers,et al.  Practice Guidelines : Evaluation of the Patient for Liver Transplantation , 2005 .

[2]  T. Berg,et al.  Comparison of adefovir and tenofovir in the treatment of lamivudine‐resistant hepatitis B virus infection , 2004, Hepatology.

[3]  W. Cooksley,et al.  Treatment with Interferons (including Pegylated Interferons) in Patients with Hepatitis B , 2004, Seminars in liver disease.

[4]  T. Wright Clinical trial results and treatment resistance with lamivudine in hepatitis B. , 2004, Seminars in liver disease (Print).

[5]  William M. Lee,et al.  Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. , 2004, Gastroenterology.

[6]  D. Samuel Management of hepatitis B in liver transplantation patients. , 2004, Seminars in liver disease.

[7]  R. Rubin,et al.  Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. , 2004, Gastroenterology.

[8]  S. Locarnini Molecular virology of hepatitis B virus. , 2004, Seminars in liver disease.

[9]  A. Lok,et al.  Hepatitis B virus genotypes in the United States: results of a nationwide study. , 2003, Gastroenterology.

[10]  Angeline Bartholomeusz,et al.  Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. , 2003, Gastroenterology.

[11]  C. Gibbs,et al.  Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil , 2003 .

[12]  Y. Chao,et al.  Peginterferon α‐2a (40 kDa): an advance in the treatment of hepatitis B e antigen‐positive chronic hepatitis B , 2003, Journal of viral hepatitis.

[13]  R. Perrillo Hepatitis B: Treatment strategies for currently available drugs , 2003 .

[14]  N. Leung,et al.  219 Results of a one-year international phase IIB comparative trial of telbivudine, lamivudine, and the combination, in patients with chronic hepatitis B , 2003 .

[15]  E. Schiff,et al.  Histological outcome during long-term lamivudine therapy. , 2003, Gastroenterology.

[16]  E. Schiff,et al.  Sustained viral load and ALT reduction following 48 weeks of entecavir treatment in subjects with chronic hepatitis B who have failed lamivudine. , 2002 .

[17]  A. Andriulli,et al.  Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study. , 2002, Journal of hepatology.

[18]  B. McMahon,et al.  Chronic hepatitis B , 2001, Hepatology.

[19]  S. Nair,et al.  Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B: Is sustained clearance of HBV DNA dependent on levels of pretreatment viremia? , 2001, Hepatology.

[20]  R. Perrillo Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. , 2001, Gastroenterology.

[21]  Ding‐Shinn Chen,et al.  Hepatitis B genotypes and the response to interferon therapy. , 2000, Journal of hepatology.

[22]  R. D. de Man,et al.  Acute Exacerbation of Chronic Hepatitis B Virus Infection After Withdrawal of Lamivudine Therapy , 2000, Hepatology.

[23]  E. Schiff,et al.  Adefovir dipivoxil for the treatment of lamivudine‐resistant hepatitis B mutants , 2000, Hepatology.

[24]  A. Dhillon,et al.  Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial , 2000, Gut.

[25]  D. Pillay,et al.  Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient , 2000, Gut.

[26]  R. Schinazi,et al.  Enhanced Antiviral Benefit of Combination Therapy with Lamivudine and Alpha Interferon against WHV Replication in Chronic Carrier Woodchucks , 1999, Antiviral therapy.

[27]  E. Jury EASL International Consensus Conference on Hepatitis C , 1999, Journal of hepatology.

[28]  E. Schiff,et al.  Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. , 1995, Gastroenterology.

[29]  A. Detsky,et al.  Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B , 1993, Annals of Internal Medicine.

[30]  F. Iber Hepatology: A Textbook of Liver Disease , 1983 .